SCHEMBL13720554

SCHEMBL13720554

CN(C[C@]1(c2cccc(Cl)c2)C[C@@H]1CC=O)C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
SLC6A4 P31645 3/20 0.35
SLC6A3 Q01959 2/20 0.35
SLC6A2 P23975 1/20 0.35
AHCY P23526 1/20 0.35
RIPK1 Q13546 1/20 0.33
TACR3 P29371 2/20 0.33
HTR2C P28335 3/20 0.33
HSD11B1 P28845 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2B P41595 1/20 0.33
USP30 Q70CQ3 1/20 0.32
STS P08842 1/20 0.32
CCR5 P51681 1/20 0.32
MCHR1 Q99705 1/20 0.31
SIRT2 Q8IXJ6 1/20 0.31
SIRT1 Q96EB6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13721085 1.00 CPB2 (0.38) CPB2SMN1; SMN2TDP1SLC6A4SLC6A3
SCHEMBL4021855 0.86 TACR3 (0.39) SMN1; SMN2TDP1SLC6A4SLC6A3SLC6A2
SCHEMBL4022865 0.86 TACR3 (0.39) SMN1; SMN2TDP1SLC6A4SLC6A3SLC6A2
SCHEMBL4024991 0.80 L3MBTL1 (0.41) CPB2SLC6A4RIPK1TACR3HTR2C
SCHEMBL6172602 0.80 CCR2 (0.36) SMN1; SMN2TDP1SLC6A4SLC6A3SLC6A2
SCHEMBL13720388 0.74 SLC6A4 (0.36) SLC6A4SLC6A3SLC6A2HTR2CUSP30
SCHEMBL13720136 0.74 SLC6A4 (0.36) SLC6A4SLC6A3SLC6A2HTR2CUSP30
SCHEMBL13720416 0.74 SLC6A4 (0.36) SLC6A4SLC6A3SLC6A2HTR2CUSP30
SCHEMBL4681356 0.74 SLC6A4 (0.36) SLC6A4SLC6A3SLC6A2HTR2CUSP30
SCHEMBL13720163 0.74 SLC6A4 (0.36) SLC6A4SLC6A3SLC6A2HTR2CUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569579-B2 for inhibition of HIV replication and treatment of acquired immune deficiency syndrome SMITHKLINE BEECHAM CORPORATION (US) 2009-08-04 US disclosed
US-7569579-B2 for inhibition of HIV replication and treatment of acquired immune deficiency syndrome SMITHKLINE BEECHAM CORPORATION (US) 2009-08-04 US disclosed
EP-1569934-B1 CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2008-01-23 EP disclosed